BUSINESSMay 26 · 11:29 UTCSTAT NEWSAndrew Joseph

STAT+: Eli Lilly to buy three small vaccine developers

Eli Lilly announced it will acquire three early- and mid-stage vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—for up to nearly $4 billion. The acquisitions follow recent purchases in cancer, autoimmune diseases, and sleep disorders, leveraging Lilly's cash reserves from its successful GLP-1 business.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Eli LillyorganizationCurevoorganizationLimmaTech BiologicsorganizationVaccine CompanyorganizationGLP-1 businesstopiccancertopicautoimmune diseasestopicsleep disorderstopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSMay 26 · 11:50 UTC
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
BUSINESSMay 7 · 08:34 UTC
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
BUSINESSMay 8 · 19:29 UTC
STAT+: Roche to buy PathAI for $750 million
BUSINESSMay 4 · 14:28 UTC
UCB to acquire maker of antibody treatments for autoimmune diseases
BUSINESSMay 12 · 07:48 UTC
STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs
BUSINESSMay 21 · 19:52 UTC
Aquarian Seeks More Backers for $4.1 Billion Brighthouse Deal